- Home
- WELL vs PFE Comparison
WELL vs PFE Comparison
Compare WELL & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WELL | PFE |
|---|---|---|
| Founded | 1970 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.1B | 145.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WELL | PFE |
|---|---|---|
| Price | $190.49 | $26.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 10 |
| Target Price | ★ $203.90 | $27.90 |
| AVG Volume (30 Days) | 3.6M | ★ 51.9M |
| Earning Date | 10-27-2025 | 02-03-2026 |
| Dividend Yield | 1.58% | ★ 6.65% |
| EPS Growth | N/A | ★ 131.89 |
| EPS | 1.46 | ★ 1.73 |
| Revenue | $9,907,853,000.00 | ★ $62,785,000,000.00 |
| Revenue This Year | $30.93 | N/A |
| Revenue Next Year | $17.66 | N/A |
| P/E Ratio | $127.98 | ★ $14.97 |
| Revenue Growth | ★ 32.28 | 3.89 |
| 52 Week Low | $123.11 | $20.92 |
| 52 Week High | $209.05 | $27.69 |
Technical Indicators
Market Signals| Indicator | WELL | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 62.99 |
| Support Level | $183.60 | $25.13 |
| Resistance Level | $205.55 | $26.19 |
| Average True Range (ATR) | 4.18 | 0.49 |
| MACD | -2.68 | 0.06 |
| Stochastic Oscillator | 26.84 | 96.96 |
Price Performance
Historical ComparisonAbout WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,391 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.